

DEC-22-03 MON 02:13 PM BOZICEVIC

FAX NO. 650 327 3231

RECEIVED
CENTRAL FAX CENTER

DECP 01 2003

OFFICIAL

Please type a plus sign (+) inside this box -> +

F-10/SB/21 (05-03)

Approved for use through 04/30/2003 GMB 0051-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

	Application Number	09/898,745	
	Filing Date	July 3, 2001	
	Confirmation Number	3662	
	First Named Inventor	DAVIS, RONALD W.	
	Group Art Unit	1637	
	Examiner's Name	STRZELECKA, TERESA E.	
Total Number of Pages in This Submission	7	Attorney Docket Number	STAN-153

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Supplemental Amendment <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interventions <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks:		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS LLP
Signature	
Date	December 22, 2003

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile filed under 37 C.F.R. §§ 1.6(d) and 1.8(a)(1)(b) addressed to: P.O. Box 1450 Alexandria VA 22313-1450 on this date: December 22, 2003
Facsimile No.: (703) 272-9300

Typed or Printed Name	Martha Cisneros	Date
		12/22/03
Signature		

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

DEC-22-03 MON 02:14 PM BOZICEVIC

FAX NO. 650 327 3231


RECEIVED
CENTRAL FAX CENTER

P. 02
DEC 22 2003

OFFICIAL

CERTIFICATE OF FAX-SIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile filed under 37 C.F.R. §§ 1.6(d) and 1.8(a)(1)(b) addressed to: P.O. Box 1450 Alexandria VA 22313-1450 on this date: December 22, 2003. Facsimile No.: (703) 872-9306

Typed or Printed Name	Mariha Cisneros		
Signature		Date	12/22/03
SUPPLEMENTAL AMENDMENT		Attorney Docket Confirmation No.	STAN-153 3662
		First Named Inventor	Ronald W. Davis
		Application Number	09/898,745
		Filing Date	July 3, 2001
		Group Art Unit	1637
		Examiner Name	Teresa E. Strzelecka
		Title	"Identification of Drugs and Drug Targets by Detection of the Stress Response"
Address to: Mail Stop: AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			

Dear Sir:

This amendment is supplemental to the amendment filed July 16, 2003 which was responsive to the Final Office Action dated April 16, 2003. Because the prior amendment was fully responsive to the last action, applicants submit that no extensions of time are required.

In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested.

Atty Dkt. No.: STAN-153
USSN: 09/898,745

AMENDMENTS

In the Claims

1. (Currently Amended) A method for identifying a bioactive compound, the method comprising the steps of:

contacting a yeast host cell containing a heterozygous deletion in a target sequence with a candidate bioactive compound; and

detecting expression of a stress response gene by the host cell in response to said contacting, wherein the stress response gene is at least one of *HSP26*, *HSP12*, *HSP42*, *HSP78*, *HSP82*, *YBR072W*, *YBL049W*, *YFL030W*, *YGR043C*, *YHR096C*, *YLR142W*, *YMR081C*, *YMR107W*, *YNL194C*, *YJL144W*, *YLR080W*, *YLR178C* or *YMR090W*;

wherein detection of no significant increase in expression of the stress response gene as compared to expression of the stress response gene in a control host cell indicates that the candidate bioactive compound has activity as a drug and that the host cell having the heterozygous deletion is sensitive to the drug activity of the compound.

2.-3. (Cancelled)

4. (Currently Amended) The method of claim 1, wherein the yeast host cell comprises a stress response gene reporter construct, wherein expression of the stress response gene reporter construct is indicative of expression of the stress response gene a stress response in the yeast host cell.

5. -- 6. (Cancelled)

7. (Currently Amended) The method of claim 1, wherein at least two or more yeast host cells, each having a heterozygous deletion in a different target sequence, are contacted with a candidate bioactive compound drug, and wherein expression of a reporter gene construct in each yeast host cell provides for a unique detectable signal for detection of reporter stress response gene expression.